These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 26558613)

  • 1. QSAR studies in the discovery of novel type-II diabetic therapies.
    Abuhammad A; Taha MO
    Expert Opin Drug Discov; 2016; 11(2):197-214. PubMed ID: 26558613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The importance of synthetic drugs for type 2 diabetes drug discovery.
    Safavi M; Foroumadi A; Abdollahi M
    Expert Opin Drug Discov; 2013 Nov; 8(11):1339-63. PubMed ID: 24050217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative structure-activity relationship: promising advances in drug discovery platforms.
    Wang T; Wu MB; Lin JP; Yang LR
    Expert Opin Drug Discov; 2015 Dec; 10(12):1283-300. PubMed ID: 26358617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in quantitative structure-activity relationship models of anti-Alzheimer's agents.
    Ambure P; Roy K
    Expert Opin Drug Discov; 2014 Jun; 9(6):697-723. PubMed ID: 24754675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative structure-activity relationship (QSAR) and design of novel ligands that demonstrate high potency and target selectivity as protein tyrosine phosphatase 1B (PTP 1B) inhibitors as an effective strategy used to model anti-diabetic agents.
    Arthur DE; Ejeh S; Uzairu A
    J Recept Signal Transduct Res; 2020 Dec; 40(6):501-520. PubMed ID: 32397858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of QSAR and Virtual Screening Studies in Type 2 Diabetes Drug Discovery.
    Pantaleao SQ; Fujii DGV; Maltarollo VG; da C Silva D; Trossini GHG; Weber KC; Scott LPB; Honorio KM
    Med Chem; 2017; 13(8):706-720. PubMed ID: 28530546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling and informatics in designing anti-diabetic agents.
    Bharatam PV; Patel DS; Adane L; Mittal A; Sundriyal S
    Curr Pharm Des; 2007; 13(34):3518-30. PubMed ID: 18220788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Latest advances in molecular topology applications for drug discovery.
    Zanni R; Galvez-Llompart M; García-Domenech R; Galvez J
    Expert Opin Drug Discov; 2015; 10(9):945-57. PubMed ID: 26134383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using computer-aided drug design and medicinal chemistry strategies in the fight against diabetes.
    Semighini EP; Resende JA; de Andrade P; Morais PA; Carvalho I; Taft CA; Silva CH
    J Biomol Struct Dyn; 2011 Apr; 28(5):787-96. PubMed ID: 21294589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thoughts on the progression of type 2 diabetes drug discovery.
    Bhatt HB
    Expert Opin Drug Discov; 2015 Feb; 10(2):107-10. PubMed ID: 25534140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational design and synthesis of new tetralin-sulfonamide derivatives as potent anti-diabetics and DPP-4 inhibitors: 2D & 3D QSAR, in vivo radiolabeling and bio distribution studies.
    Abd El-Karim SS; Anwar MM; Syam YM; Nael MA; Ali HF; Motaleb MA
    Bioorg Chem; 2018 Dec; 81():481-493. PubMed ID: 30243239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. QSAR methods for the discovery of new inflammatory bowel disease drugs.
    García-Domenech R; Gálvez-Llompart M; Zanni R; Recio MC; Gálvez J
    Expert Opin Drug Discov; 2013 Aug; 8(8):933-49. PubMed ID: 23668227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lead Optimization Resources in Drug Discovery for Diabetes.
    Tiwari P; Katyal A; Khan MF; Ashraf GM; Ahmad K
    Endocr Metab Immune Disord Drug Targets; 2019; 19(6):754-774. PubMed ID: 30834844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multitasking models for quantitative structure-biological effect relationships: current status and future perspectives to speed up drug discovery.
    Speck-Planche A; Cordeiro MN
    Expert Opin Drug Discov; 2015 Mar; 10(3):245-56. PubMed ID: 25613725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel approaches to drug discovery for the treatment of type 2 diabetes.
    Xu X; Wang G; Zhou T; Chen L; Chen J; Shen X
    Expert Opin Drug Discov; 2014 Sep; 9(9):1047-58. PubMed ID: 25054271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of computer-aided drug design in modern drug discovery.
    Macalino SJ; Gosu V; Hong S; Choi S
    Arch Pharm Res; 2015 Sep; 38(9):1686-701. PubMed ID: 26208641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The advancement of multidimensional QSAR for novel drug discovery - where are we headed?
    Wang T; Yuan XS; Wu MB; Lin JP; Yang LR
    Expert Opin Drug Discov; 2017 Aug; 12(8):769-784. PubMed ID: 28562095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidiabetic agents: past, present and future.
    Mehanna A
    Future Med Chem; 2013 Mar; 5(4):411-30. PubMed ID: 23495689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges with multi-objective QSAR in drug discovery.
    Lambrinidis G; Tsantili-Kakoulidou A
    Expert Opin Drug Discov; 2018 Sep; 13(9):851-859. PubMed ID: 29996683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cheminformatics in the Identification of Drug Classes for the Treatment of Type 2 Diabetes.
    Finn PW
    Methods Mol Biol; 2020; 2076():71-84. PubMed ID: 31586322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.